Figure 2
Figure 2. TORC1/TORC2 signaling in activated lymphocytes. (A) Schematic representing a simplified signaling pathway for TORC1/TORC2 (using ScienceSlides objects, Suite 2009). The dotted green line indicates that the signaling is not direct. (B) AKT and p70S6K phosphorylation in LPS-stimulated (48 hours) cells from spleens and LNs of KI versus WT mice. p-p70S6K levels remained low, as in unstimulated cells, whereas pAKT levels increased. (C) AKTSer473 phosphorylation in LPS-stimulated (48 hours) B220+ lymphocytes from spleens, LNs, and BM increased in KI mice compared with WT. (D) Time course (0, 15, and 30 minutes) of pAKTSer473 induction in splenocytes stimulated with LPS. (E) pAKTSer473 levels in control/untreated L363 myeloma cells versus cells treated with 10nM rapamycin for 24 hours. (F) ILK and DNA-PKcs in B220+ splenocytes stimulated with LPS after 24 hours. (G) pAKTSer473 induction (48 hours) in cells pretreated for 2 hours with 20μM of the DNA-PKcs inhibitor NU7026 and then stimulated with LPS.

TORC1/TORC2 signaling in activated lymphocytes. (A) Schematic representing a simplified signaling pathway for TORC1/TORC2 (using ScienceSlides objects, Suite 2009). The dotted green line indicates that the signaling is not direct. (B) AKT and p70S6K phosphorylation in LPS-stimulated (48 hours) cells from spleens and LNs of KI versus WT mice. p-p70S6K levels remained low, as in unstimulated cells, whereas pAKT levels increased. (C) AKTSer473 phosphorylation in LPS-stimulated (48 hours) B220+ lymphocytes from spleens, LNs, and BM increased in KI mice compared with WT. (D) Time course (0, 15, and 30 minutes) of pAKTSer473 induction in splenocytes stimulated with LPS. (E) pAKTSer473 levels in control/untreated L363 myeloma cells versus cells treated with 10nM rapamycin for 24 hours. (F) ILK and DNA-PKcs in B220+ splenocytes stimulated with LPS after 24 hours. (G) pAKTSer473 induction (48 hours) in cells pretreated for 2 hours with 20μM of the DNA-PKcs inhibitor NU7026 and then stimulated with LPS.

Close Modal

or Create an Account

Close Modal
Close Modal